This CBD Market is Expected to Grow 400% Over the Next Eight Years

August 27, 2019 - By: Baystreet Staff


Global CBD growth is expected to explode. In fact, according to Arcview Market Research and BDS Analytics, global spending on cannabis could reach $57 billion by 2027. All as consumers around the world wake up to the health benefits of cannabis, including the treatment of insomnia, stress, anxiety, pain, and even chronic issues. In Europe, for example, the market is on course to grow 400% over the next four years, according to the Brightfield Group. "CBD is just starting to take hold in Europe, with both product availability and consumer awareness still quite limited. This is a great opportunity for developed brands to enter and expand through Europe with far less competition than we're seeing in the U.S.” That’s opening a wide range of opportunity for companies such as The Yield Growth Corp. (CSE:BOSS) (OTC:BOSQF), Green Growth Brands Inc. (CSE:GGB)(OTC:GGBXF), Charlotte’s Web Holdings Inc. (OTC:CWBHF)( CN:CWEB), Aurora Cannabis Inc. (NYSE:ACB)(TO:ACB), and OrganiGram Holdings Inc. (TSXV:OGI)(NASDAQ:OGI).

The Yield Growth Corp. (CSE:BOSS)(OTCQB:BOSQF) BREAKING NEWS: The Yield Growth Corp. just announced it has entered into a distribution and licensing agreement dated August 25, 2019 with 2699598 Ontario Corp. DBA Melorganics Hellas for European rights to six product formulas for CBD infusion for a fee of $900,000. Yield has agreed to license to Melorganics in perpetuity the non-exclusive rights to formulas and know how to manufacture and distribute CBD foot cream, CBD body oil, CBD muscle relief balm, CBD body exfoliant, CBD relief gel and CBD hand cream. The formulas may be developed by Melorganics into products infused with CBD and other cannabinoids and distributed throughout the European Union under one brand to be developed by Melorganics.

“We are excited to expand our relationship with Melorganics to bring our CBD products into Europe both as a new brand to be developed and also through the Wright & Well Brand,” says Penny Green, CEO of Yield Growth. “The quality of our products and strength of our brands allow us to continue to generate revenues and build our assets to bring value to our shareholders.” Yield Growth has also agreed to grant Melorganics exclusive distribution rights to the Wright & Well brand of CBD products for the territory of Greece and Cypress for a term of two years for a fee of $100,000, payable after a definitive distribution agreement is signed between the parties and after at least 3 Wright & Well products have been registered for sale within the European Union.

Other CBD developments from around the global markets include:

Green Growth Brands Inc. (CSE:GGB)(OTC:GGBXF) just announced that it opened its 100th Seventh Sense Botanical Therapy mall-based shop on Thursday, August 8. The first Seventh Sense shop opened in early February. “This is a huge milestone for Green Growth Brands and Seventh Sense,” said Peter Horvath, CEO of Green Growth Brands. “We believe we have created the largest and most valuable network of brick and mortar CBD shops in the country.” Seventh Sense shops retail high-quality botanical therapy CBD-infused personal care and beauty products at affordable prices. The product offering includes over 100 SKUs across bath, body, face, therapeutic, and sleep categories.

Charlotte’s Web Holdings Inc. (OTC:CWBHF)( CN:CWEB) just announced expansion plans underway in 2019 including cultivation, production, distribution and R&D to support its forecasted sales growth. Most recent expansion initiatives include a building lease signed on a newly constructed 136,610-square-foot industrial building located at 700 Tech Court in the Colorado Technology Center in Louisville, Colorado. The new location enables the Company to prepare for production, distribution and R&D expansion to meet increasing demand from the consumer and national retailer channels. Charlotte's Web will commence a staged build-out of the facility during Q3-2019 and continuing over a two-year period. The staged buildout of production and distribution capacities align with product demand growth. This facility will add cumulatively to the Company's existing locations in and around the Boulder, Colorado area. Along with distribution and R&D, the large cGMP-grade building will encompass the Company's new manufacturing operations, substantially adding to the current capacity of the Company's current 40,000 sq. ft. footprint.

Aurora Cannabis Inc. (NYSE:ACB)(TO:ACB) just announced that it has secured commitments from an expanded syndicate of lenders led by the Bank of Montreal to amend and  upsize its existing C$200 million secured credit facility. The amended secured credit facility will consist of an additional C$160 million allocated between both term loans and a revolving credit facility, both of which will mature in August 2021. Closing of the credit facility is subject to completion of definitive documentation and satisfaction of conditions precedent customary for a financing of this nature. The credit facility will have a first ranking general security interest in the assets of Aurora. The Loans can be repaid without penalty at Aurora's discretion.  "The upsizing of our credit facility to approximately C$360 million and the broadening of the lending syndicate to include additional Schedule 1 Canadian Banks is further recognition that our best-in-class production facilities lead the industry," said Glen Ibbott, CFO of Aurora.  "Access to this non-dilutive capital is a core funding source the Company intends to utilize as it further executes on its strategic growth initiatives. In addition to cash being generated from operations, the Company also has access to other unsecured debt alternatives, a number of equity investments, and has access to a C$514 million (US$400 million) At-The-Market equity program.”

OrganiGram Holdings Inc. (TSXV:OGI)(NASDAQ:OGI) just announced it entered into an advance payment and purchase agreement with 703454 N.B. Inc. (carrying on business as 1812 Hemp) under which the Company will pre-fund hemp purchases to receive access to as much as 60,000 kilograms of dried hemp flower to be harvested in calendar 2019 for extraction into cannabidiol isolate.  Organigram is already a party to a purchase agreement entered into in January 2019 with 1812 Hemp, in which Organigram was granted a right of first refusal on 1812 Hemp’s production of certain hemp cultivars. Access to CBD-rich hemp flower is being facilitated through the Payment Agreement as the Company will advance funds to 1812 Hemp for their purchase of specialized large-scale hemp harvesting and processing equipment to maximize crop yields, contribute to increased efficiency and improve preservation of harvested cannabinoids. Purchase conditions for the dried hemp flower continue to be governed by the January Purchase Agreement which secures supply and supports research and development on the genetic improvement of hemp through traditional plant breeding methods.

Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media which has a partnership with www.MarijuanaStox.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media, which has a partnership with www.MarijuanaStox.com, is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media (partners of MarijuanaStox.com) and The Yield Growth Corp, Winning Media has been paid four thousand dollars for advertising and marketing services for The Yield Growth Corp. We own ZERO shares of The Yield Growth Corp. Please click here for full disclaimer.

Contact Information:
2818047972
[email protected]

News & Analysis